BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Heart failure clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for heart failure: 302 (173 sponsors; 44 newly posted in the last 180 days, 9 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 9.9, rank 71 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 19, Phase 2 37, Phase 3 32, Phase 4 2, N/A 212.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 9 | NA 5, P3 3, P4 1 | 2 | 2 |
| Novo Nordisk A/S NVO | 8 | P3 3, P2 3, P1 2 | 1 | 3 |
| Tenax Therapeutics, Inc. TENX | 3 | P3 3 | 0 | 0 |
| Bayer | 6 | NA 4, P3 2 | 0 | 1 |
| Boehringer Ingelheim | 4 | NA 2, P3 2 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 4 | NA 1, P1 1, P3 2 | 0 | 1 |
| Merck Sharp & Dohme LLC MRK | 3 | P3 2, P2 1 | 1 | 0 |
| HELP Therapeutics Co., Ltd. | 4 | P2 3, P3 1 | 0 | 0 |
| Eli Lilly and Company LLY | 3 | P2 1, P3 1, P1 1 | 1 | 0 |
| Tasly Pharmaceutical Group Co., Ltd | 3 | P3 1, P2 2 | 1 | 2 |
| Cytokinetics CYTK | 2 | P3 1, P2 1 | 0 | 0 |
| Amgen AMGN | 1 | P3 1 | 0 | 0 |
| Applied Therapeutics, Inc. AMAT | 1 | P3 1 | 0 | 0 |
| Ascendis Pharma A/S ASND | 1 | P3 1 | 0 | 0 |
| Biopeutics Co., Ltd | 1 | P3 1 | 0 | 0 |
| Braveheart Bio, Inc. BRVE new entrant | 1 | P3 1 | 1 | 0 |
| CSL Behring | 1 | P3 1 | 0 | 0 |
| Pharmacosmos A/S | 1 | P3 1 | 0 | 0 |
| Pierre Fabre Medicament | 1 | P3 1 | 0 | 0 |
| Pulnovo Medical (Wuxi) Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Seismic Pharmaceuticals Operations LLC | 1 | P3 1 | 0 | 0 |
| X4 Pharmaceuticals XFOR | 1 | P3 1 | 0 | 0 |
| Abbott Medical Devices | 8 | NA 8 | 1 | 3 |
| Edwards Lifesciences EW | 6 | NA 6 | 1 | 2 |
| Impulse Dynamics | 6 | NA 6 | 0 | 0 |
New-entrant sponsors: Braveheart Bio, Inc..
Recently stopped trials
- NCT03180450 Sclnow Biotechnology Co., Ltd. - suspended: Others The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)
- NCT06765226 Abiomed Inc. - terminated: Following an interim review, the sponsor determined that the current study design would not adequately address the study objectives. The stu Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
- NCT05636176 Novo Nordisk A/S - terminated: No longer looking for participants. A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- NCT04600791 CVRx, Inc. - terminated: Slow enrollment BATwire Implant Kit Study
- NCT06995144 Sarfez Pharmaceuticals, Inc. - withdrawn: No participants enrolled Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
- NCT04502316 CVRx, Inc. - terminated: Participant follow-up through 12 months post-Barostim Implant sufficient for data collection and analysis purposes. Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
- NCT05953831 Cardior Pharmaceuticals GmbH - withdrawn: Transfer of study responsibility and planning Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- NCT05318105 Nuwellis, Inc. - terminated: The study was stopped early due to slow enrollment and was a business decision. This decision was not based on any efficacy or safety concer Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT04331769 Ancora Heart, Inc. - suspended: Recruitment on hold pending modifications to the clinical investigation plan Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Fail
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-24 est. | P2 | Tectonic Therapeutic TECX | NCT06616974 A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction | active not recruiting | 191 |
| 2026-12 est. | P1/P2 | Iperboreal Pharma Srl | NCT03994874 Peritoneal Ultrafiltration in Cardio Renal Syndrome. | Congestive Heart Failure | recruiting | 84 |
| 2026-12 est. | P1/P2 | BioCardia, Inc. BCDA | NCT05925608 Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells | Heart Failure, Systolic | active not recruiting | 39 |
| 2026-12 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06820099 Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity | Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesi | recruiting | 225 |
| 2026-12 est. | P2 | Cardiac Success | NCT06851949 Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure | Heart Failure With Reduced Ejection Fraction | recruiting | 20 |
| 2026-12-14 est. | P2 | Bristol-Myers Squibb BMY | NCT06122779 Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure | active not recruiting | 227 |
| 2026-12-31 est. | P2 | Tasly Pharmaceutical Group Co., Ltd | NCT06669169 Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure | Heart Failure | not yet recruiting | 288 |
| 2026-12-31 est. | P1/P2 | Tasly Pharmaceutical Group Co., Ltd | NCT07265349 A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure | Coronary Artery Bypass Grafting (CABG); Chronic Heart Failure; Chronic Ischemic Cardiomyopathy | recruiting | 51 |
| 2026-12-31 est. | P2 | Sinotau Pharmaceutical Group | NCT07443696 PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy | Ischemic Cardiomyopathy; Heart Failure | recruiting | 40 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-10 est. | P1/P2 | HELP Therapeutics Co., Ltd. | NCT06340048 Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure | Heart Failure | active not recruiting | 36 |
| 2026-10-31 est. | P2 | Salubris Biotherapeutics Inc | NCT06369298 Study of JK07 in Patients With Chronic Heart Failure | Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction | active not recruiting | 282 |
| 2026-10-31 est. | P2 | AskBio Inc | NCT05598333 Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure | Congestive Heart Failure | active not recruiting | 150 |
| 2026-10-01 est. | P3 | Novo Nordisk A/S NVO | NCT06200207 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Heart Failure; Systemic Inflammation | active not recruiting | 673 |
| 2026-09-24 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced E | active not recruiting | 141 |
| 2026-09-03 | P3 | Novo Nordisk A/S NVO | NCT05636176 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Heart Failure | terminated | 4874 |
| 2026-09 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07318103 Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention | Fluid Retention Caused by Heart Failure | recruiting | 153 |
| 2026-09 est. | P2 | Cytokinetics CYTK | NCT06793371 AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | recruiting | 60 |
| 2026-08-30 | P1/P2 | Implicit Bioscience | NCT06556810 IC14 for Treatment of Acute Decompensated Heart Failure | Acute Decompensated Heart Failure | completed | 10 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "heart failure"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.